Azithromycin in the treatment of children with chronic inflammatory lung disease (CILD) Source: Eur Respir J 2004; 24: Suppl. 48, 391s Year: 2004
Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002
The effect of 3 months oral clarithromycin on sputum bacterial colonization in stable moderate- to- severe chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001
The beta-blockers in combined treatment of coronary heart disease in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD treatment Year: 2013
Cilomilast is efficacious in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 68s Year: 2003
Can we predict the outcomes of treatment of patients with severe exacerbation of chronic obstructive pulmonary disease (COPD)? Source: Eur Respir J 2001; 18: Suppl. 33, 241s Year: 2001
Use of metoprolol succinate in patients with cardiovascular diseases associated with asthma or chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 502s Year: 2006
Patient’s knowledge about risk factors for acute exacerbation( AE ) of chronic obstructive pulmonary disease( COPD ) Source: Eur Respir J 2004; 24: Suppl. 48, 514s Year: 2004
Prevalence of chronic rhinosinusitis in COPD stable patients Source: Annual Congress 2006 - COPD comorbidity Year: 2006
Efficacy of erdosteine (E) in the treatment of exacerbated and stable chronic bronchitis or chronic obstructive pulmonary disease (CB/COPD): a meta-analysis of individual patient data Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
The relationship between fibroblasts and airway structure in patients with asthma and chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 148s Year: 2001
Enalapril in the management of patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 241s Year: 2003
Almost half the patients treated for pulmonary tuberculosis (TB) show evidence of obstructive airways disease (OAD) Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control Year: 2007
The safety of sputum induction in patients with exacerbation of severe and very severe COPD (chronic obstructive pulmonary disease) Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008
The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015
The metabolic syndrome (MetS) in patients with chronic obstructive pulmonary disease (COPD) and its association with airway obstruction Source: Annual Congress 2012 - COPD is not a pulmonary disease alone Year: 2012
Smoking and airway inflammation in asymptomatic subjects and in patients with chronic airway disease Source: Eur Respir J 2002; 20: Suppl. 38, 90s Year: 2002
The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008
Bronchiectasis impact outcomes in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008
Salmeterol, added to usual therapy, is an effective bronchodilator over 12 months of treatment in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002